Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

SOUTHERN IDAHO PAIN INSTITUTE P.C.

NPI: 1932381522 · TWIN FALLS, ID 83301 · Specialist · NPI assigned 12/05/2007

$800K
Total Medicaid Paid
15,966
Total Claims
15,056
Beneficiaries
7
Codes Billed
2018-01
First Month
2023-02
Last Month

Provider Details

Authorized OfficialDILLE, CLINTON (M.D./ANESTHESIOLOGIST)
NPI Enumeration Date12/05/2007

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 2,643 $138K
2019 2,944 $108K
2020 3,090 $144K
2021 3,464 $179K
2022 3,313 $196K
2023 512 $35K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 6,675 6,201 $352K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 2,795 2,717 $167K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2,802 2,725 $103K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 2,387 2,223 $88K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 940 860 $81K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 339 305 $6K
62323 28 25 $3K